Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients. - Test2 - elhamkhani - TriplyDB

Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients.

Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients.

http://www.wikidata.org/entity/Q37486319

about

Maraviroc: a review of its use in HIV infection and beyond CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.Pregnancy is associated with elevation of liver enzymes in HIV-positive women on antiretroviral therapy.Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment.CCR5 blockade for neuroinflammatory diseases--beyond control of HIV.Effectiveness, safety, durability and immune recovery in a retrospective, multicentre, observational cohort of ART-experienced, HIV-1-infected patients receiving maraviroc.Preclinical discovery and development of maraviroc for the treatment of HIV.Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial.Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305).Effects of Maraviroc versus Efavirenz in Combination with Zidovudine-Lamivudine on the CD4/CD8 Ratio in Treatment-Naive HIV-Infected Individuals.Pharmacokinetics, Safety, and Efficacy of Maraviroc in Treatment-Experienced Pediatric Patients Infected With CCR5-Tropic HIV-1.

P2860

Q26778504-859C5C38-AF39-4378-8A49-6E20058590AB Q34360012-7DD6FF8D-EAA7-4D76-80D8-056594DBCEDA Q35629349-800B0967-B800-4652-B04E-E78091FE3D77 Q36868170-70C6FC20-B432-4528-B563-91A70A5F7A44 Q38702121-CF408594-0F13-46FC-97B1-D3A4819B1142 Q38970509-CC210DE2-A565-406D-8D25-B97A72054BBD Q39556338-1508516B-22DF-4668-B502-4C1FB2CB8F30 Q40084752-EE4665E7-91ED-477D-9628-DFB973068858 Q40464768-39BBDEE8-B158-4EA0-96E7-E9738ED635BC Q41989387-6E116A3F-159E-409D-B8E8-2BC75503E4B5 Q42696471-037E18D0-6789-43CB-B138-4AF2AABCC7D7

P2860

Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients.

http://www.wikidata.org/entity/Q37486319

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Five-year safety evaluation of ...... reatment-experienced patients.

@en

Five-year safety evaluation of ...... reatment-experienced patients.

@nl

type

label

Five-year safety evaluation of ...... reatment-experienced patients.

@en

Five-year safety evaluation of ...... reatment-experienced patients.

@nl

prefLabel

Five-year safety evaluation of ...... reatment-experienced patients.

@en

Five-year safety evaluation of ...... reatment-experienced patients.

@nl

P1433

Q37486319-46460AC1-0449-43AB-8D45-B46BD7A5DEF7

P1476

Q37486319-222C12A1-47C9-42F6-816E-6A062C06431C

P2093

Q37486319-05B759E2-77C8-475F-B40F-30E6D22AE670

Q37486319-2D537A62-9513-4180-B4EB-BE5A63A0F819

Q37486319-30A3586C-D1F9-4C81-8E44-C1B4F855B7EB

Q37486319-348BF63E-3FDA-4BAF-851E-FFAB58A23306

Q37486319-4845C815-250A-45C7-87F2-07B8D61DF4C6

Q37486319-5CDF4D1C-FFC3-4FF4-B346-557A3FCA9C8B

Q37486319-636356DC-01CA-4DB3-9897-D250235DFCDA

Q37486319-C0B50C70-05FB-46EE-94B8-999E0AAB33B0

Q37486319-D172D5E2-621F-4D94-91CA-BA288870B424

P2860

Q37486319-0BE22B72-60D2-40B2-AA12-8ECFC70DEA80

Q37486319-16C87AFB-4B7C-4460-A2B3-9D24D1404F31

Q37486319-73D3D39D-8A5E-4408-9D5D-FC4AE3DC96AD

Q37486319-B9EACB57-7C3B-441B-996D-A966D919FB8A

Q37486319-BCDD4D46-2125-4563-B655-01A5960690C4

Q37486319-C9A7F9D5-A6CB-46FE-9E03-4700850CF5EB

Q37486319-E2DDC3B0-05CB-497A-B5DF-FF835AABA8C8

Q37486319-EC8AEF54-9791-40CC-8D5B-432D9D4CD066

P304

Q37486319-B73444BE-5517-49B8-88D9-4D6E731011E0

P31

Q37486319-542699D2-7836-4A4F-B820-2BC2AB5B3E7C

P356

Q37486319-21DC27C7-2AFC-4D70-A2DB-D9371805E9A7

P407

Q37486319-C699CD11-CC8C-4014-B86D-39BEBDAB3B22

P433

Q37486319-F590D34A-AA8F-4E5D-AEAB-B01915E07176

P478

Q37486319-771106D3-B556-4959-BC6B-D858E2ADBAFF

P577

Q37486319-6EDDD0D9-A588-4BF1-B713-4B22494A71AF

P698

Q37486319-8E1A164F-0951-4D3E-BBCE-2A336EA8C63C

P921

Q37486319-1E703EEE-BE42-49E4-BC7F-09304B18D292

Q37486319-C0A51590-BB7C-4A16-9A6F-E92CBEBEE123

P932

Q37486319-75B4B21F-94B9-4CB7-ADD4-30EFDE7C460B

P356

QAI.0B013E3182A7A97A

P1433

Journal of Acquired Immune Deficiency Syndromes

P1476

Five-year safety evaluation of ...... reatment-experienced patients.

@en

P2093

Geoffrey Mukwaya

http://www.w3.org/2001/XMLSchema#string

Gerd Fatkenheuer

http://www.w3.org/2001/XMLSchema#string

James Goodrich

http://www.w3.org/2001/XMLSchema#string

Jayvant R Heera

http://www.w3.org/2001/XMLSchema#string

Mark R Nelson

http://www.w3.org/2001/XMLSchema#string

Robert Burnside

http://www.w3.org/2001/XMLSchema#string

Roy M Gulick

http://www.w3.org/2001/XMLSchema#string

Simon Portsmouth

http://www.w3.org/2001/XMLSchema#string

W David Hardy

http://www.w3.org/2001/XMLSchema#string

P2860

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients.

Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study.

Maraviroc for previously treated patients with R5 HIV-1 infection

Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2.

Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials.

Hepatic safety and tolerability in the maraviroc clinical development program.

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

P304

78-81

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAI.0B013E3182A7A97A

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24419064

http://www.w3.org/2001/XMLSchema#string

P921

P932

3893710

http://www.w3.org/2001/XMLSchema#string